John Schmid Biography and Net Worth

Director of AnaptysBio

John Schmid has more than 35 years of experience in financial and senior management in the biotech industry and has raised more than $900 million in private and public equity as well debt financings as a Chief Financial Officer. He has taken two companies public as a CFO and over the past six years, he has been involved in six IPOs as an independent board member. He is currently also a Board Member for Design Therapeutics (Nasdaq: DSGN), and Bright Peak Therapeutics, serving as the Audit Chair. Mr. Schmid also serves on the Boards of Forge Therapeutics and Speak, Inc.

Mr. Schmid has previously served on the boards of Poseida Therapeutics and Helix Acquisition Corp, II. Previously, he was the Chief Financial Officer of Auspex Pharmaceuticals which he joined in 2013 and took public in early 2014 before it was sold to Teva in 2015 for $3.5 billion. Prior to Auspex, Mr. Schmid co-founded Trius Therapeutics in 2004 where he served as CFO through its IPO and until its sale to Cubist Pharmaceuticals in 2013 for over $700 million. Before Trius, he was CFO of GeneFormatics and Endonetics (acquired by Medtronic) as well as an Associate with Idanta Partners, a venture capital firm, Vice President at HomeFed Bank and a Financial Analyst for Manufacturers Hanover (now part of J.P. Morgan) in New York. He is a past President and a past board member of the San Diego Venture Group.

Mr. Schmid received a BA in Economics from Wesleyan University and an MBA from the University of San Diego.

What is John P. Schmid's net worth?: The estimated net worth of John P. Schmid is at least $2.04 million as of March 30th, 2026. Mr. Schmid owns 31,622 shares of AnaptysBio stock worth more than $2,044,299 as of April 8th. This net worth approximation does not reflect any other investments that Mr. Schmid may own. Learn More about John P. Schmid's net worth.
How do I contact John P. Schmid?: The corporate mailing address for Mr. Schmid and other AnaptysBio executives is 10421 PACIFIC CENTER COURT SUITE 200, SAN DIEGO CA, 92121. AnaptysBio can also be reached via phone at (858) 362-6295 and via email at [email protected]. Learn More on John P. Schmid's contact information.
Has John P. Schmid been buying or selling shares of AnaptysBio?: John P. Schmid has not been actively trading shares of AnaptysBio during the last ninety days. Most recently, John P. Schmid sold 20,645 shares of the business's stock in a transaction on Monday, March 30th. The shares were sold at an average price of $56.11, for a transaction totalling $1,158,390.95. Following the completion of the sale, the director now directly owns 31,622 shares of the company's stock, valued at $1,774,310.42. Learn More on John P. Schmid's trading history.
Who are AnaptysBio's active insiders?: AnaptysBio's insider roster includes Daniel Faga (President & CEO), Dennis Fenton (Director), Paul Lizzul (Chief Medical Officer), Eric Loumeau (COO), Magda Marquet (Director), Dennis Mulroy (CFO), Hollings Renton (Director), John Schmid (Director), Hamza Suria (CEO), and J. Ware (Director). Learn More on AnaptysBio's active insiders.
Are insiders buying or selling shares of AnaptysBio?: In the last twelve months, insiders at the biotechnology company sold shares 25 times. They sold a total of 215,529 shares worth more than $9,995,735.02. The most recent insider tranaction occured on March, 30th when Director John P Schmid sold 20,645 shares worth more than $1,158,390.95. Insiders at AnaptysBio own 33.5% of the company. Learn More about insider trades at AnaptysBio.
Information on this page was last updated on 3/30/2026.

John P. Schmid Insider Trading History at AnaptysBio

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
3/30/2026	Sell	20,645	$56.11	$1,158,390.95	31,622

John P. Schmid Buying and Selling Activity at AnaptysBio

AnaptysBio Company Overview

AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis. The company also focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has a collaboration and license agreement with GlaxoSmithKline, Inc. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.

Today's Range

Now: $65.54

$62.72

$65.93

50 Day Range

MA: $56.84

$47.41

$67.29

2 Week Range

Now: $65.54

$15.40

$68.39

Volume

565,593 shs

Average Volume

550,954 shs

Market Capitalization

$1.88 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.4